Furthermore, the treatment of MDA-MB-453 breast cancer cells with monoclonal antibodies against HSP90 significantly inhibits the metastatic potential by disrupting the interaction of MMPs with HSP90 [106]. Here, HSP90AA1 is linked to breast carcinoma.